MedPath

Cardiol Therapeutics Inc

🇨🇦Canada
Ownership
-
Employees
22
Market Cap
-
Website
Introduction

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the \"ARCHER\" trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

thedeepdive.ca
·

Cardiol Therapeutics Sees Insider Buying From Leadership Team And Board Members

Cardiol Therapeutics insiders, including CEO David Elsley and CFO Christopher Waddick, have recently purchased shares, following positive Phase II trial results showing significant improvements in pericarditis treatment. The drug is advancing into Phase III trials for recurrent pericarditis and acute myocarditis.
entrepreneur.com
·

3 Penny Stocks Ready to Break Out in 2025

Investors should be cautious with penny stocks due to high risk and potential scams. Vuzix Corp. (NASDAQ: VUZI) secured a major contract and launched Z100 smart glasses. GeoVax Labs Inc. (NASDAQ: GOVX) reported positive Phase 2 trial results for a COVID vaccine candidate and received a $400 million BARDA award. Cardiol Therapeutics Inc. (NASDAQ: CRDL) is preparing for late-stage trials of CardiolRx for pericarditis treatment and was added to PRISM's Emerging Biotech Index. Sustainability and profitability are crucial for penny stock success.
thedeepdive.ca
·

Game-Changing Solution for Heart Inflammation?

Cardiol Therapeutics' CEO, David Elsley, discusses CardiolRx™, an oral therapy for recurrent pericarditis and acute myocarditis, highlighting Phase 2 trial results showing pain reduction and decreased inflammation. Upcoming Phase 2/3 trial results expected in 2025 could expedite market entry under FDA's orphan drug designation.
webdisclosure.com
·

Cardiol Therapeutics Secures Buy Rating Amid Promising Trial Results

First Berlin Equity Research maintains 'BUY' on Cardiol Therapeutics Inc. with a target price of USD 8.50, citing excellent phase II MAvERIC-Pilot study data for CardiolRx in recurrent pericarditis. 71% of patients remained recurrence-free on CardiolRx monotherapy, with high tolerance and adherence rates. Market undervalues Cardiol’s progress, with anticipation for acute myocarditis phase II study results by early 2025.
globenewswire.com
·

Trends in the $6 Billion Botanical Drugs Industry, 2030

The Botanical Drug Market grew from USD 3.75 billion in 2023 to USD 4.01 billion in 2024, expected to reach USD 6.01 billion by 2030 with a CAGR of 6.96%. Key growth factors include increased research investments, regulatory advancements, and rising awareness of herbal medicines. The market faces challenges such as limited clinical trial data and competition from conventional pharmaceuticals. Opportunities lie in expanding product lines and entering untapped markets in developing nations.

Cardiol Therapeutics' CardiolRx Gains Buy Rating on Positive Phase 2 Results and Strong

Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Cardiol Therapeutics (CRDL) with a $9.00 price target, citing positive clinical results from the MAvERIC-Pilot study, which showed significant improvements in pericarditis pain and inflammation, supporting the advancement of CardiolRx into late-stage trials.
streetwisereports.com
·

Biotech Initiates Phase III Trial for Heart Disease Drug

Cardiol Therapeutics announced Phase II MAvERIC-pilot study results showing sustained improvements in pericarditis pain and inflammation with CardioRx. The study enrolled 27 participants, with data supporting the initiation of a Phase III trial. Analysts maintain positive ratings, highlighting the drug's sustained efficacy and safety. The global cardiovascular drugs market is projected to grow significantly by 2033.
thedeepdive.ca
·

Cardiol To Advance CardiolRx To Phase III Trial Following Positive Results

Cardiol Therapeutics' CardiolRx™ showed significant improvements in pericarditis pain and inflammation in a phase II trial, supporting planned Phase III trials for prevention of recurrence. The drug was safe and well-tolerated, with potential to offer a more accessible treatment option for pericarditis patients.

Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy

Cardiol Therapeutics announced positive Phase II MAvERIC-Pilot study results for CardiolRx in treating pericarditis, with sustained pain and inflammation reduction over 26 weeks, supporting upcoming Phase III trials.
investingnews.com
·

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis

Amgen presents new data on UPLIZNA for IgG4-RD and KRYSTEXXA for uncontrolled gout at ACR Convergence 2024, highlighting reduced disease activity and shorter infusion times.
© Copyright 2025. All Rights Reserved by MedPath